natgillin/translations-raw huggingface dataset:
Accidental exposure of Healthcare Professionals (HCPs) to IMLYGIC
Nenamerna izpostavljenost zdravstvenih delavcev zdravilu IMLYGIC.
Accidental exposure to freezing temperatures for a single period of less than 24 hours does not adversely affect the stability of Neupopeg.
Če je Neupopeg pomotoma izpostavljen temperaturam pod lediščem za enkratno obdobje, ki ne preseže 24 ur, to ne škoduje njegovi stabilnosti.
Accidental ingestion can be lethal for children.
Nenamerno zaužitje je lahko za otroka smrtno.
Accidental ingestion can be lethal for children.
Nenamerno zaužitje je lahko za otroke usodno.
Accidental ingestion can be lethal for children.
Nenamerno zaužitje je lahko za otroke življenjsko nevarno.
Accidental ingestion can be lethal for children.
Nezgodno zaužitje je lahko za otroke smrtno.
Accidental ingestion may cause side effects.
Nenamerno zaužitje lahko povzroči neželene učinke.
Accidental ingestion of the entire contents of a bottle of OPATANOL would deliver a maximum systemic exposure of 5 mg olopatadine.
Nezgodno zaužitje celotne vsebine kapalnega vsebnika zdravila OPATANOL bi vodilo do največje sistemske izpostavljenosti 5 mg olopatadina.
accidental inhalation of food with risk of pneumonia (lung infection),
naključno vdihanje hrane s tveganjem za pljučnico (okužba pljuč),
Accidental injection is dangerous
Nenamerno samoinjiciranje je nevarno.
Accidental injection is dangerous - see package insert before use for further information and additional warnings.
Nenamerno injiciranje je nevarno - pred uporabo preberite priložena navodila.
Accidental injection is dangerous – read package leaflet before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite navodilo za uporabo.
Accidental injection is dangerous – read the package leaflet before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite navodilo za uporabo.
Accidental injection is dangerous – read the package leaflet before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite navodilo za uporabo:
Accidental injection is dangerous – see package insert before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite priložena navodila.
Accidental injection is dangerous – see package insert before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite priloženo navodilo.
Accidental injection is dangerous – see package leaflet before use.
Nenamerno injiciranje je nevarno – pred uporabo preberite navodilo za uporabo.
Accidental injection is dangerous – see package leaflet before use.
Nenamerno samoinjiciranje je nevarno – pred uporabo preberite navodilo za uporabo.
Accidental injection is dangerous.
Nenamerno samoinjiciranje je nevarno.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger.
Nenamerno injiciranje lahko povzroči hude bolečine in otekline, zlasti če se zdravilo injicira v sklep ali prst – in lahko v izjemnih primerih privede do izgube prsta.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger.
Nenamerno injiciranje lahko povzroči hudo bolečino in otekanje, še posebej če je bilo injiciranje izvedeno v sklep ali prst, kar lahko v redkih primerih privede do izgube prsta.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger.
Nenamerno injiciranje lahko povzroči hudo bolečino in otekanje, še posebno če pride do injiciranja v sklep ali prst na roki - redko povzroči izgubo prsta.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger.
Nenamerno vbrizganje lahko povzroči hudo bolečino in otekanje, predvsem če se zdravilo vbrizga v sklep ali prst – redko povzroči izgubo prsta.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – this could result in the loss of the finger if prompt medical attention is not given.
Nenamerno injiciranje lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst na roki – brez takojšnje zdravniške oskrbe lahko pride do izgube prsta.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nenamerno injiciranje/samo- injiciranje lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst, in lahko v izjemnih primerih, če ni zagotovljena takojšnja zdravniška oskrba, privede do izgube prizadetega prsta.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nenamerno injiciranje/samo-injiciranje lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst in lahko v redkih primerih, če ni zagotovljena takojšnja zdravniška oskrba, privede do izgube prizadetega prsta.
Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nenamerno injiciranje/samoinjiciranje lahko povzroči hude bolečine in otekline, zlasti ob injiciranju v sklep ali prst, in lahko v izjemnih primerih, če ni zagotovljena takojšnja zdravniška oskrba, privede do izgube prizadetega prsta.
accidental injury, impaired healing
naključne poškodbe, slabše celjenje
accidental loss or leakage of urine
naključno uhajanje seča
Accidental one-time exposure to freezing temperatures does not adversely affect the stability of Accofil.
Nenamerna enkratna izpostavljenost temperaturam v območju zmrzišča nima vpliva na stabilnost zdravila Accofil.
accidental overdose
nenamerno preveliko odmerjanje
Accidental overdose of enoxararin sodium after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Nenamerno preveliko odmerjanje natrijevega enoksaparinata po intravenskem, zunajtelesnem ali subkutanem dajanju lahko povzroči zaplete s krvavitvami.
Accidental overdose of this medicine after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Nenamerno preveliko odmerjanje tega zdravila po intravenskem, zunajtelesnem ali subkutanem dajanju lahko povzroči zaplete s krvavitvami.
Accidental self-injection can provoke clinical signs of hypoglycaemia and there is a low possibility of an allergic reaction in sensitised individuals.
Nenamerno samo-injiciranje lahko izzove klinične znake hipoglikemije in obstaja majhna možnost alergijske reakcije pri občutljivih osebah.
Accidental self-injection is dangerous
Nenamerno injiciranje je nevarno.
Accidental self-injection is dangerous
Nenamerno samoinjiciranje je nevarno.
Accidental self-injection is dangerous – see package insert
Nenamerno injiciranje je nevarno – preberite priloženo navodilo.
Accidental self-injection is dangerous.
Nenamerno injiciranje je nevarno.
Accidental self-injection is dangerous.
Nenamerno samo-injiciranje je nevarno.
Accidental self-injection is dangerous.
Nenamerno samoinjiciranje je nevarno.
Accidental self-injection may give rise to pain.
Nenamerna samoinjiciranje lahko povzroči bolečino.
Accidentally falling
Nezgodni padec
Accidentally ingestion can be lethal for children.
Nenamerno zaužitje kapsul lahko pri otrocih povzroči smrt.
Accidentally taking too much Lamivudine Teva is unlikely to cause any serious problems.
Če pomotoma vzamete prevelik odmerek zdravila Lamivudin Teva, je malo verjetno, da bi prišlo do kakršnihkoli resnih težav.
accidents, coma, speech and language abnormalities, paralysis and paresis, amnesia
govora in jezika, paraliza in pareza, amnezija
Accofil 30 MU/0.5 ml
Accofil 30 M e./0,5 ml
Accofil 30 MU/0.5 ml (0.6 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 30 M e./0,5 ml (0,6 mg/ml) raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi filgrastim
Accofil 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil 30 M e./0,5 ml raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi
Accofil 30 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 30 M e./0,5 ml raztopina za injiciranje/infundiranje filgrastim
Accofil 48 MU/0.5 ml
Accofil 48 M e./0,5 ml
Accofil 48 MU/0.5 ml (0.96 mg/ml) solution for injection or infusion in pre-filled syringe filgrastim
Accofil 48 M e./0,5 ml (0,96 mg/ml) raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi filgrastim
Accofil 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Accofil 48 M e./0,5 ml raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi
Accofil 48 MU/0.5 ml solution for injection/infusion filgrastim
Accofil 48 M e./0,5 ml raztopina za injiciranje/infundiranje filgrastim
Accofil containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Zdravilo Accofil , ki vsebuje r- metHuG-CSF (filgrastim), v 24 urah izrazito poveča število nevtrofilcev v periferni krvi; število monocitov pa se ob tem le nekoliko poveča.
Accofil contains no preservative.
Zdravilo Accofil ne vsebuje konzervansov.
Accofil is a biosimilar medicinal product.
Zdravilo Accofil je podobno biološko zdravilo.
Accofil is available in packs containing 1, 3, 5, 7 and 10 pre-filled syringes, with prefixed needle safety guard in individual blister pack or without needle safety guard / blister and alcohol swabs.
Zdravilo Accofil je na voljo v pakiranjih, ki vsebujejo 1, 3, 5, 7 in 10 napolnjenih injekcijskih brizg, z vnaprej nameščeno varnostno zaščito za iglo v posameznem pretisnem omotu ali brez varnostne zaščite za iglo/pretisnega omota, in alkoholne krpice.
Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).
Zdravilo Accofil je indicirano za izplavljanje krvotvornih matičnih celic v periferno kri (PBPC - peripheral blood progenitor cells).
Accofil must not be diluted with saline solutions.
Zdravila Accofil ne smemo mešati s fiziološko raztopino.
Accofil should not be diluted with sodium chloride solution.
Zdravila Accofil ne smemo mešati z raztopino natrijevega klorida.
Accofil therapy should only be given in collaboration with an oncology centre which has experience in granulocyte-colony stimulating factor (G-CSF) treatment and haematology and has the necessary diagnostic facilities.
Zdravljenje z zdravilom Accofil se lahko predpiše samo v sodelovanju z onkološkim centrom, ki ima izkušnje na področju zdravljenja s faktorji, ki spodbujajo rast granulocitnih kolonij (G-CSF - granulocyte-colony stimulating factor) in hematologije, in ki razpolaga z ustreznimi diagnostičnimi pripomočki.
Accofil treatment will last for 4 to 5 days.
Zdravljenje z zdravilom Accofil bo trajalo 4 do 5 dni.
Accofil treatment will last for up to 2 weeks.
Zdravljenje z zdravilom Accofil bo trajalo do 2 tedna.
Accofil, which contains the active substance filgrastim, is a ‘biosimilar medicine’.
Zdravilo Accofil, ki vsebuje zdravilno učinkovino filgrastim, je „biološko podobno“ zdravilo.
Accommodation disorder
motnje akomodacije
accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation
jih spremlja zvišanje vrednosti direktnega bilirubina, ali jih spremljajo klinični simptomi okvare jeter ali znaki jetrne dekompenzacije.
accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation.
ga spremlja zvišanje direktnega bilirubina ali ga spremljajo klinični simptomi okvare jeter ali znaki jetrne dekompenzacije.
Accord
Accord (logotip)
Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow,
Accord Healthcare Limited Sage House, 319, Pinner Road
Accord Healthcare Limited Sage house, 319, Pinner road North Harrow
Accord Healthcare Limited, Sage house, 319, Pinner road North Harrow
Accord Healthcare Limited,
Accord Healthcare Limited
Accord Healthcare Limited, Sage house, 319 Pinner road, North Harrow,
Accord Healthcare Limited Sage house, 319 Pinner Road,
Accord Healthcare Limited, Sage House, 319 Pinner Road, North Harrow,
PfizerAccord Healthcare Limited, Sage House, 319 Pinner Road, North Harrow,
Accord Healthcare Ltd Ground Floor
Accord Healthcare Limited Ground floor,
According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Glede na farmakokinetično študijo pri bolnikih z rakom, ki imajo blago ali zmerno jetrno okvaro zaradi zasevkov v jetrih, je biološka uporabnost kapecitabina in izpostavljenost 5-FU lahko povečana v primerjavi z bolniki brez okvare.
According to an independent review committee (IRC) assessment of patients with ALK-positive NSCLC (N=1669), 20 (1.2%) patients had ILD/pneumonitis, including 10 (<1%) patients with fatal cases.
Glede na oceno bolnikov z ALK-pozitivnim NSCLC (n = 1.699) neodvisnega odbora za pregled (IRC – Independent Review Committee) je 20 (1,2 %) bolnikov imelo ILD/pnevmonitis, vključno z 10 (< 1 %) bolniki s smrtnim izidom.
According to Article 71 of Directive 2001/82/EC as amended, Member States prohibit or may prohibit the import, sale, supply and/or use of the veterinary medicinal product on the whole or part of their territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta, države članice prepovejo ali lahko prepovejo uvoz, prodajo, oskrbo in/ali uporabo zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če se ugotovi da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta z vsemi dopolnitvami in spremembami države članice prepovejo ali lahko prepovejo uvoz, prodajo, oskrbo in/ali uporabo zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če ugotovijo, da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of their territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta z vsemi dopolnitvami in spremembami lahko država članica skladno z nacionalno zakonodajo prepove izdelavo, uvoz/vnos, posedovanje, prodajo, oskrbo in/ali uporabo imunološkega zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če ugotovi da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of the immunological veterinary medicinal products on the whole or part of their territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta, z vsemi dopolnitvami in spremembami lahko država članica, skladno z nacionalno zakonodajo, prepove izdelavo, uvoz/vnos, posedovanje, prodajo, oskrbo in/ali uporabo imunološkega zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če ugotovi da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member States may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of their territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta z vsemi dopolnitvemi in spremembami lahko država članica, skladno z nacionalno zakonodajo, prepove izdelavo, uvoz/vnos, posedovanje, prodajo, oskrbo in/ali uporabo imunološkega zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če ugotovi da:
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, Member States prohibit or may prohibit the import, sale, supply and/or use of the veterinary medicinal product on the whole or part of their territory if it is established that:
Skladno s členom 71 Direktive 2001/82/ES Evropskega parlamenta in Sveta države članice prepovejo ali lahko prepovejo uvoz, prodajo, oskrbo in/ali uporabo zdravila za uporabo v veterinarski medicini na svojem celotnem ozemlju ali delu ozemlja, če se ugotovi da:
According to clinical response and tolerability, after a minimum of 2 days the dose may be increased by 200 mg/day, to the maximum recommended dose of 600 mg/day (15 ml/day).
Glede na klinični odziv in prenašanje zdravila lahko čez najmanj 2 dni odmerek povečamo za 200 mg/dan do največjega priporočenega odmerka, ki je 600 mg/dan (15 ml/dan).
According to clinical response and tolerability, after a minimum of 2 days the dose may be increased by 200 mg/day, to the maximum recommended dose of 600 mg/day.
Glede na klinični odziv in prenašanje zdravila lahko čez najmanj 2 dni odmerek zvečamo za 200 mg/dan na največji priporočeni odmerek, ki je 600 mg/dan.
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day (25 ml/day).
Glede na klinični odziv in prenašanje zdravila lahko odmerek postopoma povečujemo po 200 mg/dan celo vsak drugi dan do največjega priporočenega odmerka 1.000 mg/dan (25 ml/dan).
According to clinical response and tolerability, the dose may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum recommended dose of 1000 mg/day.
Glede na klinični odziv in prenašanje zdravila lahko odmerek povečujemo postopoma po 200 mg/dan celo vsak drugi dan do največjega priporočenega odmerka 1.000 mg/dan.
According to clinical response and tolerability, the dose may be increased by 400 mg/day increments, as frequently as every two days, up to a maximum recommended dose as indicated in the table below.
Glede na klinični odziv in prenašanje zdravila lahko odmerek povečujemo postopoma po 400 mg/dan celo vsak drugi dan do največjega priporočenega odmerka, navedenega v spodnji preglednici.
According to current guidelines, medicines that have been shown to be effective in patients with PID and in patients with ITP can also be approved for use in the treatment of all types of primary immunodeficiency, as well as low antibody levels due to blood cancers and AIDS in children.
V skladu z veljavnimi smernicami se lahko zdravila, ki so se izkazala kot učinkovita pri bolnikih s sindromom primarne imunske pomanjkljivosti in bolnikih z idiopatsko trombocitopenično purpuro, odobrijo tudi za uporabo pri zdravljenju vseh vrst primarne imunske pomanjkljivosti ter tudi nizkih ravni protiteles zaradi krvnega raka ali aidsa pri otrocih.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
Glede na trenutne terapevtske smernice dvotirno zdravljenje z zaviralci proteaz praviloma ni priporočljivo.
According to epidemiological findings, a higher incidence of cardiovascular events has been associated with certain indicators, for instance:
Po epidemioloških izsledkih je večja incidenca kardiovaskularnih pojavov povezana z določenimi pokazatelji, npr.:
According to literature reports, it may be considered that both spermatogenetic and genetic damage in male testis are unlikely at the dose of 1,000 MBq.
Glede na poročila iz strokovne literature se lahko sklepa, da je pri odmerku 1000 MBq le majhna verjetnost za spermatogenetske in genetske okvare v moških testisih.
According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratory- confirmed clinical influenza among children was significantly reduced from 19 % (21/111) in the group not receiving prevention to 7 % (7/104) in the group receiving prevention (64.4 % reduction [95 % CI 15.8 – 85.0; p = 0.0188]).
Glede na analizo podskupin pri otrocih, starih od 1 do 12 let, je bila pojavnost klinične laboratorijsko potrjene influence med otroci značilno zmanjšana iz 19 % (21/111) v skupini, ki ni prejemala zdravila za preprečevanje, na 7 % (7/104) v skupini, ki je prejemala zdravilo za preprečevanje gripe (64,4-% znižanje 95-% interval zaupanja 15,8–85,0); p = 0,0188).
According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratory- confirmed clinical influenza among children was significantly reduced from 19 % (21/111) in the group not receiving prevention to 7 % (7/104) in the group receiving prevention (64.4 % reduction [95 % CI 15.8 – 85.0; p = 0.0188]).
Glede na analizo podskupin pri otrocih, starih od 1 do 12 let, je bila pojavnost klinične laboratorijsko potrjene influence med otroci značilno zmanjšana iz 19 % (21/111) v skupini, ki ni prejemala zdravila za preprečevanje, na 7 % (7/104) v skupini, ki je prejemala zdravilo za preprečevanje gripe (64,4-% znižanje 95-% interval zaupanja 15,8–85,0; p = 0,0188).
According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratory-confirmed clinical influenza among children was significantly reduced from 19 % (21 / 111) in the group not receiving prevention to 7 % (7 / 104) in the group receiving prevention (64.4 % reduction [95 % CI 15.8 – 85.0; p = 0.0188]).
Glede na analizo podskupin pri otrocih, starih od 1 do 12 let, je bila pojavnost klinične laboratorijsko potrjene influence med otroci značilno zmanjšana iz 19 % (21/111) v skupini, ki ni prejemala zdravila za preprečevanje na 7 % (7/104) v skupini, ki je prejemala zdravilo za preprečevanje gripe (64,4-% znižanje [95-% interval zaupanja 15,8 – 85,0; p = 0,0188]).
According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum.
V skladu z dosedanjimi ugotovitvami so simptomi Parkinsonove bolezni povezani z izgubo dopamina v progastem telesu (corpus striatum).
According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).
Glede na presnovno pot aripiprazola pri kadilcih odmerka ni treba prilagajati (glejte poglavje 4.5).
According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version
Glede na skupne kriterije toksičnosti skupine za klinična preskušanja Kanadskega državnega inštituta za raka (NCIC CTG
According to the relatively low exposure, coagulation at 72 hrs (presumed dabigatran trough level at steady state or close to steady state conditions) was only slightly prolonged with aPTT at maximum 1.60 fold, ECT 1.86 fold, and Hemoclot® TT (Anti-FIIa) 1.36 fold, respectively.
Ker je bila izpostavljenost zdravilu razmeroma majhna, je bila koagulacija po 72 urah (predvidena raven dabigatrana pred naslednjim odmerkom v ravnotežnem stanju ali blizu ravnotežnega stanja) le nekoliko podaljšana, in sicer aPTČ največ 1,60-krat, EKT 1,86-krat in Hemoclot® TT (anti-FIIa) 1,36-krat.
According to this daily carbidopa dose, the maximum recommended daily 175 mg/43.75 mg/200 mg dose is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day.
175 mg/43,75 mg/200 mg je 8 tablet na dan in zdravila Corbilta 200 mg/50 mg/200 mg 7 tablet dnevno.